| Angela Christine Lucas, LPN | |
|
438 Student Health Ctr, University Park, PA 16802-2129 | |
| (814) 863-0774 | |
| (814) 865-6982 |
| Full Name | Angela Christine Lucas |
|---|---|
| Gender | Female |
| Speciality | Clinical Nurse Specialist |
| Location | 438 Student Health Ctr, University Park, Pennsylvania |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1437816998 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 364S00000X | Clinical Nurse Specialist | PN305894 (Pennsylvania) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Angela Christine Lucas, LPN 438 Student Health Ctr, University Park, PA 16802-2129 Ph: (814) 863-0774 | Angela Christine Lucas, LPN 438 Student Health Ctr, University Park, PA 16802-2129 Ph: (814) 863-0774 |
News Archive
Marriage between first cousins can more than double the risk of giving birth to a baby with a congenital anomaly (eg, heart and lung defects, Down syndrome), although the absolute risk is low, according to a multiethnic study of more than 11300 babies from the city of Bradford in the UK, published in The Lancet.
One of the Canberra orthopedic surgeons who missed out on being selected for a contract with ACT Health has alleged that the selection process is unfair. Two of the orthopedic surgeons were given contracts to work as visiting medical officers (VMO) in ACT Health. These doctors were colleagues of some members of the selection panel. The question of conflict of interest on these grounds was raised by the two unsuccessful candidates. One of them was Dr Paul Miniter.
New research says studying both adult and embryonic stem cells can benefit medical science, but banning the study of either type could harm studies of the other.
Research published in the November issue of Anesthesiology describes development of a new Risk Stratification Index (RSI) that allows important clinical outcomes such as length-of-stay and mortality for surgical patients to be accurately compared among hospitals using only publically available billing data. The new risk stratification system is more accurate than existing outcomes measurements such as the Charlson Comorbidity Index (CCI) and the investigators have made it freely available.
Biocept, Inc., an emerging leader in rare cell capture, announced today that the U.S. Patent and Trademark Office has issued a patent for Biocept's cell separation technology using a microfluidic device. U.S. patent #7,695,956 entitled "Device for Cell Separation and Analysis and Method of Using" protects Biocept's microflow device to isolate cells from a bodily fluid using a flow path where straight-line flow is interrupted by transverse posts arranged in a random pattern.
› Verified 1 days ago